


Fig. S1



**Figure S1.** Decitabine-mediated CSPG4 upregulation in Caov-3 cells and 293T cells. **(a)** CSPG4-staining of Caov-3 ovarian cancer cells using a PE-labeled anti-CSPG4 antibody and a corresponding isotype control. One representative run out of three experiments is depicted. **(b)** Contour plots showing CSPG4-staining of Caov-3 ovarian cancer cells six days after daily addition of Decitabine at 1  $\mu$ M. One representative run out of three experiments is depicted. **(c)** CSPG4-expression in Caov-3 ovarian cancer cells six days after daily addition of PBS or Decitabine at 1  $\mu$ M. Data represent geometric means  $\pm$  SEM of three runs, p values were calculated by Student's t test, \*\*\*\* indicates  $p \leq 0.0001$ . **(d)** CSPG4-staining of 293T cells using a PE-labeled anti-CSPG4 antibody and a corresponding isotype control. One representative run out of three experiments is depicted. **(e)** Contour plots showing CSPG4-staining of 293T cells six days after daily addition of PBS or Decitabine at 1  $\mu$ M. One representative run out of three experiments is depicted. **(f)** CSPG4-expression in 293T cells six days after daily addition of Decitabine at 1  $\mu$ M. Data represent geometric means  $\pm$  SEM of three runs, p values were calculated by Student's t test, \*\*\*\* indicates  $p \leq 0.0001$ .